AAV Serotype 8-Mediated Gene Delivery of a Soluble VEGF Receptor to the CNS for the Treatment of Glioblastoma

Thomas C. Harding, Alshad S. Lalani, Byron N. Roberts, Satya Yendluri, Bo Luan, Kathryn E. Koprivnikar, Melissa Gonzalez-Edick, Guang Huan-Tu, Randy Musterer, Melinda J. VanRoey, Tomoko Ozawa, Richard A. LeCouter, Dennis Deen, Peter J Dickinson, Karin Jooss

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The presence of the blood-brain barrier complicates drug delivery in the development of therapeutic agents for the treatment of glioblastoma multiforme (GBM). The use of local gene transfer in the brain has the potential to overcome this delivery barrier by allowing the expression of therapeutic agents directly at the tumor site. In this study, we describe the development of a recombinant adeno-associated (rAAV) serotype 8 vector that encodes an optimized soluble inhibitor, termed sVEGFR1/R2, of vascular endothelial growth factor (VEGF). VEGF is an angiogenic factor highly up-regulated in GBM tumor tissue and correlates with disease progression. In subcutaneous models of GBM, VEGF inhibition following rAAV-mediated gene transfer significantly reduces overall tumor volume and increases median survival time following a single administration of vector. Using orthotopic brain tumor models of GBM, we find that direct intracranial administration of the rAAV-sVEGFR1/R2 vector to the tumor site demonstrates anti-tumor efficacy at doses that are not efficacious following systemic delivery of the vector. We propose that rAAV-mediated gene transfer of a potent soluble VEGF inhibitor in the CNS represents an effective antiangiogenic treatment strategy for GBM.

Original languageEnglish (US)
Pages (from-to)956-966
Number of pages11
JournalMolecular Therapy
Volume13
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Vascular Endothelial Growth Factor Receptor
Glioblastoma
Vascular Endothelial Growth Factor A
Genes
Neoplasms
Angiogenesis Inducing Agents
Tumor Burden
Blood-Brain Barrier
Brain Neoplasms
Disease Progression
Serogroup
Brain
Therapeutics
Pharmaceutical Preparations

Keywords

  • adeno-associated virus
  • antiangiogenesis
  • brain cancer
  • gene therapy
  • glioblastoma
  • serotype 8
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Harding, T. C., Lalani, A. S., Roberts, B. N., Yendluri, S., Luan, B., Koprivnikar, K. E., ... Jooss, K. (2006). AAV Serotype 8-Mediated Gene Delivery of a Soluble VEGF Receptor to the CNS for the Treatment of Glioblastoma. Molecular Therapy, 13(5), 956-966. https://doi.org/10.1016/j.ymthe.2006.02.004

AAV Serotype 8-Mediated Gene Delivery of a Soluble VEGF Receptor to the CNS for the Treatment of Glioblastoma. / Harding, Thomas C.; Lalani, Alshad S.; Roberts, Byron N.; Yendluri, Satya; Luan, Bo; Koprivnikar, Kathryn E.; Gonzalez-Edick, Melissa; Huan-Tu, Guang; Musterer, Randy; VanRoey, Melinda J.; Ozawa, Tomoko; LeCouter, Richard A.; Deen, Dennis; Dickinson, Peter J; Jooss, Karin.

In: Molecular Therapy, Vol. 13, No. 5, 05.2006, p. 956-966.

Research output: Contribution to journalArticle

Harding, TC, Lalani, AS, Roberts, BN, Yendluri, S, Luan, B, Koprivnikar, KE, Gonzalez-Edick, M, Huan-Tu, G, Musterer, R, VanRoey, MJ, Ozawa, T, LeCouter, RA, Deen, D, Dickinson, PJ & Jooss, K 2006, 'AAV Serotype 8-Mediated Gene Delivery of a Soluble VEGF Receptor to the CNS for the Treatment of Glioblastoma', Molecular Therapy, vol. 13, no. 5, pp. 956-966. https://doi.org/10.1016/j.ymthe.2006.02.004
Harding, Thomas C. ; Lalani, Alshad S. ; Roberts, Byron N. ; Yendluri, Satya ; Luan, Bo ; Koprivnikar, Kathryn E. ; Gonzalez-Edick, Melissa ; Huan-Tu, Guang ; Musterer, Randy ; VanRoey, Melinda J. ; Ozawa, Tomoko ; LeCouter, Richard A. ; Deen, Dennis ; Dickinson, Peter J ; Jooss, Karin. / AAV Serotype 8-Mediated Gene Delivery of a Soluble VEGF Receptor to the CNS for the Treatment of Glioblastoma. In: Molecular Therapy. 2006 ; Vol. 13, No. 5. pp. 956-966.
@article{75ed5c11097142ab9b78e754d3b413e8,
title = "AAV Serotype 8-Mediated Gene Delivery of a Soluble VEGF Receptor to the CNS for the Treatment of Glioblastoma",
abstract = "The presence of the blood-brain barrier complicates drug delivery in the development of therapeutic agents for the treatment of glioblastoma multiforme (GBM). The use of local gene transfer in the brain has the potential to overcome this delivery barrier by allowing the expression of therapeutic agents directly at the tumor site. In this study, we describe the development of a recombinant adeno-associated (rAAV) serotype 8 vector that encodes an optimized soluble inhibitor, termed sVEGFR1/R2, of vascular endothelial growth factor (VEGF). VEGF is an angiogenic factor highly up-regulated in GBM tumor tissue and correlates with disease progression. In subcutaneous models of GBM, VEGF inhibition following rAAV-mediated gene transfer significantly reduces overall tumor volume and increases median survival time following a single administration of vector. Using orthotopic brain tumor models of GBM, we find that direct intracranial administration of the rAAV-sVEGFR1/R2 vector to the tumor site demonstrates anti-tumor efficacy at doses that are not efficacious following systemic delivery of the vector. We propose that rAAV-mediated gene transfer of a potent soluble VEGF inhibitor in the CNS represents an effective antiangiogenic treatment strategy for GBM.",
keywords = "adeno-associated virus, antiangiogenesis, brain cancer, gene therapy, glioblastoma, serotype 8, vascular endothelial growth factor",
author = "Harding, {Thomas C.} and Lalani, {Alshad S.} and Roberts, {Byron N.} and Satya Yendluri and Bo Luan and Koprivnikar, {Kathryn E.} and Melissa Gonzalez-Edick and Guang Huan-Tu and Randy Musterer and VanRoey, {Melinda J.} and Tomoko Ozawa and LeCouter, {Richard A.} and Dennis Deen and Dickinson, {Peter J} and Karin Jooss",
year = "2006",
month = "5",
doi = "10.1016/j.ymthe.2006.02.004",
language = "English (US)",
volume = "13",
pages = "956--966",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - AAV Serotype 8-Mediated Gene Delivery of a Soluble VEGF Receptor to the CNS for the Treatment of Glioblastoma

AU - Harding, Thomas C.

AU - Lalani, Alshad S.

AU - Roberts, Byron N.

AU - Yendluri, Satya

AU - Luan, Bo

AU - Koprivnikar, Kathryn E.

AU - Gonzalez-Edick, Melissa

AU - Huan-Tu, Guang

AU - Musterer, Randy

AU - VanRoey, Melinda J.

AU - Ozawa, Tomoko

AU - LeCouter, Richard A.

AU - Deen, Dennis

AU - Dickinson, Peter J

AU - Jooss, Karin

PY - 2006/5

Y1 - 2006/5

N2 - The presence of the blood-brain barrier complicates drug delivery in the development of therapeutic agents for the treatment of glioblastoma multiforme (GBM). The use of local gene transfer in the brain has the potential to overcome this delivery barrier by allowing the expression of therapeutic agents directly at the tumor site. In this study, we describe the development of a recombinant adeno-associated (rAAV) serotype 8 vector that encodes an optimized soluble inhibitor, termed sVEGFR1/R2, of vascular endothelial growth factor (VEGF). VEGF is an angiogenic factor highly up-regulated in GBM tumor tissue and correlates with disease progression. In subcutaneous models of GBM, VEGF inhibition following rAAV-mediated gene transfer significantly reduces overall tumor volume and increases median survival time following a single administration of vector. Using orthotopic brain tumor models of GBM, we find that direct intracranial administration of the rAAV-sVEGFR1/R2 vector to the tumor site demonstrates anti-tumor efficacy at doses that are not efficacious following systemic delivery of the vector. We propose that rAAV-mediated gene transfer of a potent soluble VEGF inhibitor in the CNS represents an effective antiangiogenic treatment strategy for GBM.

AB - The presence of the blood-brain barrier complicates drug delivery in the development of therapeutic agents for the treatment of glioblastoma multiforme (GBM). The use of local gene transfer in the brain has the potential to overcome this delivery barrier by allowing the expression of therapeutic agents directly at the tumor site. In this study, we describe the development of a recombinant adeno-associated (rAAV) serotype 8 vector that encodes an optimized soluble inhibitor, termed sVEGFR1/R2, of vascular endothelial growth factor (VEGF). VEGF is an angiogenic factor highly up-regulated in GBM tumor tissue and correlates with disease progression. In subcutaneous models of GBM, VEGF inhibition following rAAV-mediated gene transfer significantly reduces overall tumor volume and increases median survival time following a single administration of vector. Using orthotopic brain tumor models of GBM, we find that direct intracranial administration of the rAAV-sVEGFR1/R2 vector to the tumor site demonstrates anti-tumor efficacy at doses that are not efficacious following systemic delivery of the vector. We propose that rAAV-mediated gene transfer of a potent soluble VEGF inhibitor in the CNS represents an effective antiangiogenic treatment strategy for GBM.

KW - adeno-associated virus

KW - antiangiogenesis

KW - brain cancer

KW - gene therapy

KW - glioblastoma

KW - serotype 8

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33645896141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645896141&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2006.02.004

DO - 10.1016/j.ymthe.2006.02.004

M3 - Article

C2 - 16580881

AN - SCOPUS:33645896141

VL - 13

SP - 956

EP - 966

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -